The “Cicada” Variant: What BA.3.2 Means for the Future of COVID-19
A new COVID-19 subvariant, BA.3.2 – nicknamed “Cicada” – is gaining attention from global health officials. This variant, a descendant of the Omicron lineage, is being closely monitored due to its high number of mutations and potential to evade existing immunity. First detected in South Africa in late 2024, it has since spread to over 20 countries, including parts of Europe, Australia, and the United States.
Why is BA.3.2 Called “Cicada”?
The variant earned the nickname “Cicada” because of its unusual behavior. Like the insect that spends years underground before emerging, BA.3.2 remained largely undetected for nearly a year after its initial discovery before resurfacing with significant genetic changes. This prolonged period of “underground” evolution is what sparked concern among virologists.
A Deep Dive into BA.3.2’s Mutations
BA.3.2 is notable for its extensive mutation profile. It carries over 50 mutations in the spike protein compared to its ancestor and more than 70 mutations relative to the original Wuhan strain. These mutations raise concerns about potential immune escape, increased transmissibility, and changes in how the virus behaves biologically. The World Health Organization (WHO) classified BA.3.2 as a “variant under monitoring” in December 2025.
Immune Evasion and the Potential for Re-infection
Public health experts are particularly interested in BA.3.2 because preliminary assessments suggest it may partially evade immunity from prior infections or vaccinations. This doesn’t necessarily imply vaccines are ineffective, but it could reduce their ability to prevent infection altogether. However, current evidence suggests existing vaccines are still likely to protect against severe disease.
Symptoms of BA.3.2: What to Expect
So far, symptoms associated with BA.3.2 appear similar to other Omicron subvariants and are generally mild in vaccinated individuals. Common symptoms include cough, fatigue, runny nose or congestion, headache, sore throat, mild fever, and body aches. Less common symptoms may include loss of taste or smell, night sweats, and skin rashes. Health agencies note that COVID-19 symptoms continue to evolve with variants and can vary depending on vaccination status and immunity levels.
Severity: Is BA.3.2 More Dangerous?
Current evidence suggests that BA.3.2 does not cause more severe illness than previous Omicron variants. Global health data indicates no significant increase in hospitalization rates or a rise in mortality. Symptoms largely resemble mild upper respiratory infections.
Geographic Spread and Current Status
As of February 2026, BA.3.2 has been detected in at least 25 U.S. States, and in countries including Japan, Kenya, the Netherlands, and the United Kingdom. In some regions, it accounts for up to 30% of cases. While its overall prevalence remains low in the United States, detections have risen notably in parts of Europe.
What Does This Mean for the Future?
The emergence of BA.3.2 highlights the ongoing evolution of SARS-CoV-2 and the necessitate for sustained surveillance. The variant serves as a reminder that COVID-19 has not disappeared. Continued global travel and interconnected populations mean new variants can spread quickly.
FAQ: BA.3.2 and COVID-19
- Is the “Cicada” variant more dangerous? Current evidence suggests it does not cause more severe illness than previous Omicron variants.
- Will my vaccine protect me against BA.3.2? Existing vaccines are still likely to protect against severe disease, even if protection against infection may be reduced.
- What are the symptoms of BA.3.2? Symptoms are similar to other Omicron subvariants: cough, fatigue, runny nose, headache, and sore throat.
- Is BA.3.2 widespread? It has been detected in over 20 countries, including the US and parts of Europe, but currently doesn’t account for a significant percentage of cases globally.
Pro Tip: Staying up-to-date with booster recommendations is crucial for maintaining protection against evolving variants like BA.3.2.
The BA.3.2 Cicada variant is a reminder that vigilance is key. Vaccination, surveillance, and public awareness remain the most effective tools in managing emerging variants.
